Macomics, the Macrophage-based Drug Discovery company, secures £4.24m expansion financing, and appoints CEO, CSO and VP Immunology
Retrieved on:
Thursday, July 29, 2021
University, Biotechnology, Education, Professional services, Health, Pharmaceutical, Oncology, Hospitals, Other Professional Services, Clinical trials, Finance, Branches of biology, Immune system, Cell biology, Lymphatic system, Macrophage, Phagocytes, Tumor microenvironment, Macomics, the new appointments, MACOMICS, THE NEW APPOINTMENTS
Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
Key Points:
- Its target discovery platform enables identification and validation of novel macrophage therapeutic targets and is based on its deep understanding of macrophage biology.
- The tumour microenvironment changes macrophage behaviour, and the company is exploiting disease specific TAM biology to selectively target these immunosuppressive cells.
- Dr Ries joined Macomics in July 2021 and has over 20 years of immunology and drug discovery experience and is an internationally recognised expert in macrophage immunology.
- Dr Cassetta is an author of multiple publications in high-impact international scientific journals including Cancer Cell, Nature Communications, Journal of Experimental Medicine, Blood, PNAS, Nature Reviews Drug Discovery.